Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock: a Randomized, Controlled Trial

NCT07569536 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT07569536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07569536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock: a Randomized, Controlled Trial
Lead sponsor
Hospices Civils de Lyon
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
December 1, 2028
Enrollment
360 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

septic shock, vasopressor resistance